Published in Antimicrob Agents Chemother on July 01, 2003
Serine-to-asparagine substitution in the GyrA gene leads to quinolone resistance in moxifloxacin-exposed Chlamydia pneumoniae. Antimicrob Agents Chemother (2005) 0.80
Functional analysis of three topoisomerases that regulate DNA supercoiling levels in Chlamydia. Mol Microbiol (2015) 0.76
In vitro activities of garenoxacin and levofloxacin against Chlamydia pneumoniae are not affected by presence of Mycoplasma DNA. Antimicrob Agents Chemother (2004) 0.75
DNA topoisomerases. Annu Rev Biochem (1981) 13.42
Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol Microbiol (1994) 7.89
Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis (2000) 7.80
A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis (1990) 6.52
Chlamydia pneumoniae (TWAR). Clin Microbiol Rev (1995) 4.93
Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America. Clin Infect Dis (1998) 4.55
Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756. Antimicrob Agents Chemother (2000) 3.08
In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone. Antimicrob Agents Chemother (1999) 2.88
In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy (1997) 2.82
In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin. J Antimicrob Chemother (2000) 1.88
Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV purified from Staphylococcus aureus. Antimicrob Agents Chemother (1997) 1.70
Sequencing of gyrase and topoisomerase IV quinolone-resistance-determining regions of Chlamydia trachomatis and characterization of quinolone-resistant mutants obtained In vitro. Antimicrob Agents Chemother (1998) 1.31
In vitro activities of BMS-284756 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae. Antimicrob Agents Chemother (2002) 1.13
Comparative in-vitro activity of moxifloxacin, minocycline and azithromycin against Chlamydia spp. J Antimicrob Chemother (1999) 1.02
In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp. Antimicrob Agents Chemother (1997) 1.02
In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae. Antimicrob Agents Chemother (1998) 0.94
Comparative in vitro activity of garenoxacin against Chlamydia spp. J Antimicrob Chemother (2002) 0.91
In-vitro activity of gatifloxacin against Chlamydia trachomatis and Chlamydia pneumoniae. J Antimicrob Chemother (1999) 0.83
Mosaic-like structure of penicillin-binding protein 2 Gene (penA) in clinical isolates of Neisseria gonorrhoeae with reduced susceptibility to cefixime. Antimicrob Agents Chemother (2002) 2.91
Influence of inoculum size of Staphylococcus aureus and Pseudomonas aeruginosa on in vitro activities and in vivo efficacy of fluoroquinolones and carbapenems. J Antimicrob Chemother (2005) 1.30
Analysis of amino acid sequences of penicillin-binding protein 2 in clinical isolates of Neisseria gonorrhoeae with reduced susceptibility to cefixime and ceftriaxone. J Infect Chemother (2008) 1.22
Theoretical study on second hyperpolarizabilities of phenylacetylene dendrimer: toward an understanding of structure-property relation in NLO responses of fractal antenna dendrimers. J Am Chem Soc (2002) 0.95
Inhibitory activity of garenoxacin against DNA gyrase of Mycoplasma pneumoniae. J Antimicrob Chemother (2012) 0.77
Activity of Garenoxacin against Macrolide-Susceptible and -Resistant Mycoplasma pneumoniae. Antimicrob Agents Chemother (2007) 0.77
In vitro pharmacodynamic evaluation of garenoxacin against quinolone-resistant Streptococcus pneumoniae. Int J Antimicrob Agents (2011) 0.76
[Alteration of antibacterial activity of tosufloxacin and various antibacterial agents against Streptococcus pneumoniae]. Jpn J Antibiot (2003) 0.76
[In vitro and in vivo antibacterial activities of pazufloxacin mesilate, a new injectable quinolone]. Jpn J Antibiot (2002) 0.75
Exciton migration dynamics in a dendritic molecule: quantum master equation approach using ab initio molecular orbital configuration interaction method. J Chem Phys (2004) 0.75
[In vitro interaction of tazobactam/piperacillin combined with aminoglycosides against Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli AND Staphylococcus aureus]. Jpn J Antibiot (2002) 0.75
In vitro antichlamydial activity of garenoxacin against Chlamydia trachomatis. J Infect Chemother (2011) 0.75
[In vitro combination effect of pazufloxacin with various antibiotics against Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus]. Jpn J Antibiot (2002) 0.75
Pharmacodynamic evaluation of tosufloxacin against Streptococcus pneumoniae in an in vitro model simulating serum concentration. J Infect Chemother (2006) 0.75
Synthesis, antibacterial activity, and toxicity of 7-(isoindolin-5-yl)-4-oxoquinoline-3-carboxylic acids. Discovery of the novel des-F(6)-quinolone antibacterial agent garenoxacin (T-3811 or BMS-284756). Arzneimittelforschung (2002) 0.75
Bactericidal activity of garenoxacin against in vitro biofilm formed by nontypeable Haemophilus influenzae. J Infect Chemother (2012) 0.75